论文部分内容阅读
Objective:The aim of the study was to estimate the clinical value of serum interleukin-18(IL-18)and nitric oxide(NO)activities in patients with prostate cancer.Methods:The 50 patients with prostate cancer and 25 control subjects were measured in serum IL-18 by enzyme-linked immunosorbent assay(ELISA)and nitrate+nitrite level by an index of NO generation.Results:Serum IL-18 and nitrate+nitrite levels were significantly higher in patients with prostate cancer when compared to the control subjects(P<0.05).Serum IL-18 level was significantly higher in patients with stages B,C and D when compared to patients with stage A(P<0.05).Serum IL-18 level was significantly higher in the metastatic patients compared with the nonmetastatic patients(P<0.01).There was no difference in serum nitrate and nitrite level between metastatic and nonmetastatic patients(P>0.05).The serum IL-18 and nitrate and nitrite levels decreased after patients underwent surgical resection.Conclusion:Serum IL-18 level may be a useful marker to predict prognosis of patients with prostate cancer after surgery.Long-term follow-up is required to clarify this hypothesis.
Objective: The aim of the study was to estimate the clinical value of serum interleukin-18 (IL-18) and nitric oxide (NO) activities in patients with prostate cancer. Methods: The 50 patients with prostate cancer and 25 control subjects were measured in serum IL-18 by enzyme-linked immunosorbent assay (ELISA) and nitrate + nitrite level by an index of NO generation. Results: Serum IL-18 and nitrate + nitrite levels were significantly higher in patients with prostate cancer when compared to the control subjects (P <0.05) .Serum IL-18 level was significantly higher in patients with stages B, C and D when compared to patients with stage A with the nonmetastatic patients (P <0.01). There was no difference in serum nitrate and nitrite level between metastatic and nonmetastatic patients (P> 0.05). The serum IL-18 and nitrate and nitrite levels decreased after the patient underwent surgical resection. Conlusion: Serum IL-18 level may be a useful marker to predict prognosis of patients with prostate cancer after surgery. Long-term follow-up is required to clarify this hypothesis.